Healthcare Cost Containment
… policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment . Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability …
Private equity pushes into healthcare: 6 recent deals | Becker’s Hospital Review | 9/22/2020
… based Array Biostatistics. 2 Corza Health, a portfolio company of GTCR, agreed to acquire surgical patch TachoSil from Takeda Pharmaceutical. 3. FTV Capital invested in 6 Degrees Health, a Hillsboro, Ore.-based provider of healthcare cost containment solutions for self-insured employers. 4. Trinity Hunt Partners acquired MainStreet Family Urgent Care, a Birmingham, Ala.-based urgent care provider. 5. ArchiMed acquired a majority interest in NAMSA, a Northwood, Ohio-based …
… policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment . Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability …
… policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment . Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with …
… policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment . Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability …
6 Degrees Health , a provider of technology-enabled healthcare cost containment solutions for self-insured employers, today announced it has secured a significant investment from FTV Capital , a sector-focused growth equity investor in innovative companies in enterprise technology and services, financial services, and payments and transaction processing. This investment will enable 6 Degrees Health to expand its platform, which enables employers to realize significant cost savings while also generating …
6 Degrees Health Secures Significant Growth Equity Investment from FTV Capital | 9/9/2020
6 Degrees Health Secures Significant Growth Equity Investment from FTV Capital Investment will support continued growth and expansion of leading reference-based pricing platform HILLSBORO, Ore., September 9, 2020– 6 Degrees Health, a provider of technology-enabled healthcare cost containment solutions for self-insured employers, today announced it has secured a significant investment from FTV Capital, a sector-focused growth equity investor in innovative companies in enterprise technology and services …
… Pharmaceutical Industry Consumer Characteristics and Factors Affecting Demand Marketing Overview Large Purchasing/Marketing Groups Changing the Face of Medical Device Marketing Offshore Competition Contract Packaging Industry Products and Trends Overview Changing Demographics and Lifestyles Healthcare Cost Containment Overview Managed Care Cost Reimbursement Hospitals Physicians, Surgeons, etc. Drug Costs Generic Drugs Background Sales of Generic Products Generic Substitution Positive Aspects OTC Drugs Home Healthcare Solid Waste Disposal Healthcare Packaging Standards Compliance …
… policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment . Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability …
… policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment . Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability …
… policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment . Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability …
… policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment . Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with …
Amgen Announces Early Tender Results Of Senior Notes Exchange Offers | PR Newswire | 8/13/2020
… policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment . Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with …
… at the Pioneer Institute. She was also a former Senior Fellow and Associate at the Harvard Kennedy School’s Center for Business and Government where she researched and wrote about Massachusetts market reform and healthcare cost containment efforts. She served as Massachusetts Undersecretary of the Office of Consumer Affairs and Business Regulation from 2009 to 2015 and has worked at the intersection of federal and state commercial regulation and the …
… cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment , primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at …
Containing Rising Healthcare Costs in the Wake of COVID-19 | Modern Healthcare | 7/31/2020
… but there has never been a better time to engage in creative thinking about ways to contain healthcare costs and simultaneously serve the needs of vulnerable citizens. HMS has extensive experience helping states with healthcare cost containment strategies. Visit Health Ideas , our forum to discuss the latest healthcare issues and trends including our newest blog series on cost containment. Sponsored By: HMS advances healthcare by helping organizations reduce costs and …
… policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment . Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with …
… be achieved; the outcome of post-approval clinical trials; competitive developments; difficulties or delays in manufacturing; the impact of existing and future legislation and regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment ; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims and concerns that may arise regarding the safety or efficacy of the Indivior Group’s products and product candidates; risks related to …
Amgen Announces 2020 Third Quarter Dividend | PR Newswire | 7/23/2020
… policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment . Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with …
… policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment . Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with …
… be achieved; the outcome of post-approval clinical trials; competitive developments; difficulties or delays in manufacturing; the impact of existing and future legislation and regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment ; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims and concerns that may arise regarding the safety or efficacy of the Indivior Group’s products and product candidates; risks related to …
Company seeks to accelerate their growth in healthcare cost containment solutions ARNOLD, MD, June 24, Innovative Healthware Services, DBA ClaimsBridge, ( www.claimsbridge.com ), a leading healthcare technology company providing solutions that help control medical claim costs, announced that Michael Tosti has been hired to the position of Executive Vice President of Sales and Marketing. In this role, Tosti will be responsible for driving the growth of IHS’s ClaimsBridge suite of IT solutions …
… policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment . Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with …
… cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment , primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at …
PHOENIX , May 7, On Wednesday, the City of Phoenix City Council authorized the City Manager to enter into an inter-governmental agreement with the Arizona Healthcare Cost Containment System (AHCCCS) to utilize the City’s Pediatric Health Care Initiative Ordinance. The authorization continues a long partnership between Phoenix Children’s Hospital and the City of Phoenix. The Pediatric Health Care Initiative Ordinance, which was extended in 2019, enables the City to accept …
Food and Drug Administration
… providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to … is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions …
Clinical Research
… and most prescribed preventive therapy in this class, Aimovig continues to be at the forefront of preventive migraine treatment and clinical research. 5,6 These long-term results further demonstrate the potential of Aimovig to help … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our …
COVID-19
… collaborations, with any other company, including BeiGene, Ltd. or any collaboration or potential collaboration in pursuit of therapeutic antibodies against COVID-19 (including statements regarding such collaboration’s, or our own, ability to discover and develop … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our …
Medicaid
Containing Rising Healthcare Costs in the Wake of COVID-19 | Modern Healthcare | 7/31/2020
… people will lose employer-sponsored health insurance due to the pandemic. As a result, millions are likely to enroll in Medicaid as a safety net. COVID-19 has also demonstrated that income and racial disparities … of vulnerable citizens. HMS has extensive experience helping states with healthcare cost containment strategies. Visit Health Ideas , our forum to discuss the latest healthcare issues and trends including our newest blog series on cost containment …
Medicare
Containing Rising Healthcare Costs in the Wake of COVID-19 | Modern Healthcare | 7/31/2020
… African Americans are dying from COVID-19 at 2.5 times the rate of whites. Individuals who are eligible for both Medicare and Medicaid are also at higher risk for more severe cases of COVID-19 … of vulnerable citizens. HMS has extensive experience helping states with healthcare cost containment strategies. Visit Health Ideas , our forum to discuss the latest healthcare issues and trends including our newest blog series on cost containment …
Department of Health and Human Services
… stipulated injunction with the FTC, and entered into a Corporate Integrity Agreement with the Office of Inspector General of the Department of Health and Human Services (HHS). Under the terms of the agreement, the Justice … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims and concerns that may arise regarding the safety or efficacy …
Consumer Healthcare
PFIZER REPORTS FIRST-QUARTER 2020 RESULTS | Business Wire | 4/28/2020
… Meridian and Mylan-Japan are reported in Pfizer’s Upjohn business in all periods presented. Acquisitions and the contribution of Pfizer’s Consumer Healthcare business to the GSK Consumer Healthcare joint venture (JV) that were completed during … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products; the impact of any …
American Heart Association
… for greater research into the efficacy and safety of PCSK9 inhibitors in specific populations, like people living with HIV. The American Heart Association and American College of Cardiology multi-society cholesterol guidelines also identify HIV … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our …
Psychosocial Support
… a minimum of seven days. SUBLOCADE should be used as part of a complete treatment program that includes counseling and psychosocial support. 2 “This analysis offers new insight into extended-release buprenorphine treatment in patients … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims and concerns that may arise regarding the safety or efficacy …
Mental Health
… Department of Family Medicine, David Geffen School of Medicine, UCLA . “These results showed that patients experienced improvements in physical and mental health which may help in the recovery journey and positively impact lifestyle, including employment … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims and concerns that may arise regarding the safety or efficacy …
Addiction Treatment
… program that includes counseling and psychosocial support. IMPORTANT SAFETY INFORMATION Prescription use of this product is limited under the Drug Addiction Treatment Act. WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims and concerns that may arise regarding the safety or efficacy …
Mental Health Services
… in manufacturing; the impact of existing and future legislation and regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims … Department of Health and Human (HHS), Services Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment (SAMHSA). Medication-Assisted Treatment for Opioid Addiction . HHS Publication No. (SMA) 09-4443, First printed 2009. Revised …
Clinical Data
Amgen Announces Data Being Presented At ASH 2019 | PR Newswire | 12/2/2019
THOUSAND OAKS, Calif. Amgen (NASDAQ: AMGN ) today announced new clinical data from its oncology in-line products and pipeline that will be presented at the 61 st American Society of Hematology (ASH) Annual Meeting & Exposition … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our …
Biosimilars
Amgen Announces Data Being Presented At ASH 2019 | PR Newswire | 12/2/2019
… biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing …
National Cancer Institute
Amgen Announces Data Being Presented At ASH 2019 | PR Newswire | 12/2/2019
… B-ALL) were accepted as a late-breaking abstract. AALL1331 is sponsored by the Cancer Therapy Evaluation Program of the National Cancer Institute (NCI), part of the National Institutes of Health, and is conducted by … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our …
National Institutes of Health
… in manufacturing; the impact of existing and future legislation and regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims … Health and Human Services (HHS), National Institute on Drug Abuse, National Institutes of Health. Drugs, Brains, and Behavior: The Science of Addiction. HHS Publication No. (SMA) 18-5063PT5, Printed 2018. 6. Ling W, Nadipelli VR, Solem …
Substance Abuse
… injections on patient-centered outcomes: a long-term study “ was published online in the December issue of the Journal of Substance Abuse Treatment ( https://doi.org/10.1016/j.jsat.2019.11.004 ). 1 By the end of the 12 … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims and concerns that may arise regarding the safety or efficacy …
Committee for Medicinal Products for Human Use
… BRUSSELS , Oct. 17, Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) today announced that following a re-examination procedure, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen’s research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen’s …
ACA
… that it will present new long-term data of Aimovig ® (erenumab-aooe) across the migraine spectrum at the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia . Data from a one-year open-label … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen’s research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen’s …
Novartis
… nasopharyngitis, upper respiratory tract infection, and influenza. About Aimovig ® (erenumab-aooe) Aimovig, co-marketed in the U.S. by Amgen and Novartis, is the first and only FDA and EMA-approved migraine preventive treatment that targets … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our …
… operating income expected to grow low double digit Basel, July 21, 2020 - commenting on the quarter, Vas Narasimhan, CEO of Novartis, said: “Novartis performed strongly in the first half, despite the impact from COVID-19 … ophthalmology, in the second half of 2020; global trends toward healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; uncertainties regarding potential significant breaches …
Amgen
Amgen (NASDAQ:AMGN) today announced that results reinforcing the long-term safety and efficacy profile of Aimovig ® (erenumab-aooe) in patients with episodic migraine (EM) are being presented at the Migraine Trust Virtual Symposium. Results … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our …
… G12C Inhibitor News provided by Sep 20, 2020, 08:39 ET Share this article THOUSAND OAKS, Calif. , Sept. 20, 2020 /PRNewswire/ – Amgen (NASDAQ: AMGN ) today announced that updated data from the full Phase 1 cohort of … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our …
BeiGene
… statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company, including BeiGene, Ltd. or any collaboration or potential collaboration in pursuit of therapeutic antibodies against COVID … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our …
Amgen Announces 2020 Third Quarter Dividend | PR Newswire | 7/23/2020
… ability to discover and develop fully-human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19), BeiGene, Ltd., or the Otezla® (apremilast) acquisition, including anticipated Otezla sales growth and the timing … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We …
Sandoz
… United States District Court for the District of New Jersey that had upheld the validity of two patents asserted against Sandoz Inc., Sandoz International GmbH and Sandoz GmbH (together, Sandoz) based on Sandoz’s biosimilar of … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We …
… United States District Court for the District of New Jersey that had upheld the validity of two patents asserted against Sandoz Inc., Sandoz International GmbH and Sandoz GmbH (together, Sandoz) based on Sandoz’s biosimilar of … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We …
Pfizer
PFIZER REPORTS FIRST-QUARTER 2020 RESULTS | 4/28/2020
NEW YORK–(BUSINESS WIRE)–Apr 28, 2020– Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2020, reaffirmed its 2020 financial guidance for revenues and Adjusted diluted EPS (3) and updated certain other components … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products; the impact of any …
PFIZER REPORTS FIRST-QUARTER 2019 RESULTS | Business Wire | 4/30/2019
NEW YORK- Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2019 and raised the midpoint of its 2019 financial guidance for adjusted diluted EPS (2) . At the start of the 2019 fiscal year … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products; the impact of any …
Upjohn
PFIZER REPORTS FIRST-QUARTER 2020 RESULTS | Business Wire | 4/28/2020
… 2020 and 2019 (4) are summarized below. OVERALL RESULTS ($ in millions, except per share amounts) First-Quarter Beginning in 2020, Upjohn began managing Pfizer’s Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products; the impact of any …
PFIZER REPORTS FIRST-QUARTER 2019 RESULTS | Business Wire | 4/30/2019
… portfolio into its Oncology and Inflammation & Immunology business units and certain legacy established products into the Internal Medicine business unit. Upjohn, a global, off-patent branded and generic established medicines business, which includes 20 off … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products; the impact of any …
Adaptive Biotechnologies
THOUSAND OAKS, Calif. , and SEATTLE , April 7, Amgen (NASDAQ: AMGN ) and Adaptive Biotechnologies Corporation (NASDAQ: ADPT ) will participate in a webinar hosted by Bernstein on Thursday, April 9 at 8 a.m. PT ( 11 a.m. ET … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We …
THOUSAND OAKS, Calif. , and SEATTLE , April 7, 2020 /PRNewswire/ – Amgen (NASDAQ:AMGN) and Adaptive Biotechnologies Corporation (NASDAQ:ADPT) will participate in a webinar hosted by Bernstein on Thursday, April 9 at 8 a.m. PT ( 11 … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We …
Allergan
THOUSAND OAKS, Calif. , June 13, Amgen (NASDAQ: AMGN ) and Allergan plc (NYSE: AGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI ™ (trastuzumab-anns) for all approved indications of the reference … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen’s research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen’s …
Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer First Avastin® (Bevacizumab) Biosimilar Candidate Recommended for European Approval 10, 2017, 07:27 THOUSAND OAKS, Calif … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen’s research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen’s …
Brigham and Women's Hospital
… patients 1 ,” said Robert Giugliano , M.D., FOURIER executive committee member and a senior investigator at the TIMI Study Group at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School . “These results demonstrate … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our …
… achieved with statins alone,” said Marc Sabatine , M.D., chairman, TIMI Study Group, Lewis Dexter, MD Distinguished Chair in Cardiovascular Medicine, Brigham and Women’s Hospital and lead investigator of FOURIER. “These results offer additional ways for … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our …
Arvind Sood
… providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to … of the products for these uses. CONTACT: Amgen, Thousand Oaks Arvind Sood , 805-447-1060 (investors) References Ashina M, Goadsby P, Reuter U, et al. Sustained efficacy and long-term safety of erenumab in patients with episodic …
David M. Reese
… 2020. “CodeBreaK 100 is the largest Phase 1/2, and first-in-human, clinical study for a KRAS G12C inhibitor,” said David M. Reese , M.D., executive vice president of Research and Development at Amgen. “Earlier this … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our …
Walter Ling
… 2020 . “Opioid use disorder is a chronic disease and its treatment is complex and multifaceted,” said the study’s lead author, Walter Ling , MD, Research Professor, Department of Family Medicine, David Geffen School of Medicine, UCLA … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims and concerns that may arise regarding the safety or efficacy …
Robert A. Bradway
Amgen Reports First Quarter 2020 Financial Results | PR Newswire | 5/1/2020
… Amgen and others across the industry are stepping up to meet the greatest public health challenge of our lifetime,” said Robert A. Bradway , chairman and chief executive officer. “We are committed to an uninterrupted supply … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We …
Christian Heidbreder
… opioid use disorder as a chronic disease that requires services and support structures over an extended period of time,” said Christian Heidbreder , PhD, Indivior’s Chief Scientific Officer. “Data from this open-label study provide additional … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; challenges in the commercial execution; claims and concerns that may arise …
David Reese
… imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our …
Jessica Akopyan
… providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen’s research, testing, pricing, marketing and other operations are subject to … Corporate Communications, Investor Relations (415) 290-7757 CONTACT: Amgen, Thousand Oaks Jessica Akopyan, (805) 447-0974 (media) Trish Hawkins , 805-447-5631 (media) Arvind Sood , 805-447-1060 (investors) CONTACT: Servier Sonia Marques : [email protected] – Tel. +33 (0)1 55 72 …
Darryl Sleep
… are not managing one of the most important modifiable risk factors for a heart attack: high LDL-C 2 ,” said Darryl Sleep , M.D., senior vice president of Global Medical and chief medical officer at Amgen … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our …
Shaun Thaxter
… that medication, including counseling, is available to help them treat their addiction and help them keep moving towards recovery,” said Shaun Thaxter , Chief Executive Officer of Indivior. “We believe that those suffering from moderate to … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims and concerns that may arise regarding the safety or efficacy …
David Nicholson
… Herceptin. “KANJINTI is the second of four biosimilars from Amgen and Allergan’s collaboration to be approved by the FDA,” said David Nicholson , chief research and development officer at Allergan. “We are proud of the progress … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen’s research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen’s …
David Nichol
… Herceptin. “KANJINTI is the second of four biosimilars from Amgen and Allergan’s collaboration to be approved by the FDA,” said David Nicholson , chief research and development officer at Allergan. “We are proud of the progress … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen’s research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen’s …
Franco Signor
… firm focused on the business services, software and IT services sectors, today announced that it has made an investment in Franco Signor , a provider of Medicare Secondary Payer (MSP) compliance solutions to the country’s largest … Partners, said, “We recognize the importance of MSP compliance within healthcare cost containment efforts and, furthermore, recognize Franco Signor as a true leader in this space, helping its customers navigate ever-evolving and complex rules …
Sean E. Harper
FDA Approves Amgen’s Repatha® (evolocumab) To Prevent Heart Attack And Stroke | CNBC | 12/2/2017
… priority so that patients can benefit from Repatha’s ability to reduce life-changing events of heart attacks and strokes,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. “Despite treatment … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our …
Sean Harper
… imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims …
Cindy McDaniel
… are happy to award the ENBREL Mini™ cartridge with AutoTouch™ reusable autoinjector with our Ease of Use SM Commendation,” said Cindy McDaniel , senior vice president, Consumer Affairs, The Arthritis Foundation. “This distinction is awarded to … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen’s research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen’s …
Joan Lunden
… NASDAQ: AMGN ) today announced the launch of At Home with Joan , a campaign led by breast cancer survivor and advocate Joan Lunden . This campaign aims to empower patients diagnosed with cancer to be active participants … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We …
About:
Editor:
